Diatech gets peptide labeling patent

Article

Peptide imaging agent developer Diatech of Londonderry, NH, hasreceived a broad patent from the U.S. Patent and Trademark Officecovering its core technology of attaching peptides to technetium-99mradioisotopes. The patent covers Diatech's work on several

Peptide imaging agent developer Diatech of Londonderry, NH, hasreceived a broad patent from the U.S. Patent and Trademark Officecovering its core technology of attaching peptides to technetium-99mradioisotopes. The patent covers Diatech's work on several products,including agents for imaging disease states such as deep veinthrombosis, pulmonary emboli, tumors and atherosclerotic plaque.Diatech said the patent puts it in a strong proprietary positionas it works to commercialize the agents.

The company also announced this month that it has receiveda $100,000 grant from the Heart and Lung Blood Institute divisionof the National Institutes of Health to research a potential newtherapeutic agent for the treatment of blood clots.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
Current Insights on Interoperability, Enterprise Imaging and AI Integration in Radiology
A Closer Look at the Mammo Enhance Heart Program: An Interview with Arthy Saravanan, MD
Current Perspectives on Prostate Cancer and Emerging Theranostic Agents, Part 1
© 2025 MJH Life Sciences

All rights reserved.